BCL2L1 and cancer: The DNA intercalating anti-cancer drugs oxaliplatin and cisplatin switch splicing in favor of Bcl-xS (Shkreta et al., 2008), and this shift occurs through activation of the DNA damage-associated ATM/CHK2 signaling axis (Shkreta et al., 2011).